脂必泰胶囊联合匹伐他汀对冠心病患者血脂水平的影响

Influence of Zhibitai capsule combined with pitavastatin on blood lipid levels in patients with coronary heart disease

目的:观察脂必泰胶囊联合匹伐他汀对冠心病患者血脂水平的影响。方法:选择2018年3月~2021年2月间我院收治的180例冠心病患者,按照随机数字表法分为匹伐他汀组(90例)和联合治疗组(90例,脂必泰胶囊联合匹伐他汀治疗),两组均治疗8周。观察两组临床疗效、治疗前后血脂、炎症因子水平变化及不良反应发生情况。结果:联合治疗组的临床总有效率显著高于匹伐他汀组(94.44%比80.00%,P=0.001)。治疗后,与匹伐他汀组比较,联合治疗组血清总胆固醇(TC)[(4.39±0.71)mmol/L比(2.86±0.56)mmol/L]、甘油三酯(TG)[(2.28±0.43)mmol/L比(1.46±0.39)mmol/L]、低密度脂蛋白胆固醇(LDL-C)[(2.93±0.50)mmol/L比(1.84±0.52)mmol/L]、脂蛋白(a)[(124.57±11.37)mmol/L比(85.83±11.96)mmol/L]水平及白介素-6(IL-6)[(21.28±3.64)pg/ml比(12.39±2.08)pg/ml]、高迁移率族蛋白B1(HMGB1)[(3.84±0.98)μg/L比(1.28±0.79)μg/L]、肿瘤坏死因子-α(TNF-α)[(4.06±0.62)ng/ml比(2.39±0.48)ng/ml]水平均显著降低,高密度脂蛋白胆固醇(HDL-C)[(1.89±0.26)mmol/L比(2.63±0.31)mmol/L]水平显著升高(P均=0.001)。两组不良反应发生率对比无统计学差异(P=0.600)。结论:脂必泰胶囊联合匹伐他汀治疗冠心病患者,可有效调节血脂,降低炎症因子水平,安全有效。

Objective:To observe the effect of Zhibitai capsule combined with pitavastatin on blood lipid levels in patients with coronary heart disease(CHD).Methods:A total of 180 CHD patients who were treated in our hospital from Mar 2018 to Feb 2021 were selected.According to random number table method,they were divided into pitavastatin group(n=90)and combined treatment group(n=90,received Zhibitai capsule combined with pitavastatin),and both groups were treated for eight weeks.Clinical therapeutic effect,levels of blood lipids and inflammatory factors before and after treatment,and incidence of adverse reactions were observed and compared between two groups.Results:Total effective rate of combined treatment group was significantly higher than that of pitavastatin group(94.44%vs.80.00%,P=0.001).Compared with pitavastatin group after treatment,there were significant reductions in serum levels of total cholesterol(TC)[(4.39±0.71)mmol/L vs.(2.86±0.56)mmol/L],triglyceride(TG)[(2.28±0.43)mmol/L vs.(1.46±0.39)mmol/L],low density lipoprotein cholesterol(LDL-C)[(2.93±0.50)mmol/L vs.(1.84±0.52)mmol/L],lipoprotein(a)[(124.57±11.37)mmol/L vs.(85.83±11.96)mmol/L],interleukin-6(IL-6)[(21.28±3.64)pg/ml vs.(12.39±2.08)pg/ml],high mobility group box-1 protein B1(HMGB1)[(3.84±0.98)μg/L vs.(1.28±0.79)μg/L],tumor necrosis factor-α(TNF-α)[(4.06±0.62)ng/ml vs.(2.39±0.48)ng/ml],and significant rise in level of high density lipoprotein cholesterol(HDL-C)[(1.89±0.26)mmol/L vs.(2.63±0.31)mmol/L]in combined treatment group,P=0.001 all.There was no significant difference in incidence rate of adverse reactions between two groups,P=0.600.Conclusion:Zhibitai capsule combined with pitavastatin can effectively regulate blood lipids,reduce the levels of inflammatory factors in patients with coronary heart disease,which is safe and effective.